Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON)

Mia Malone, Ryan McDonald, Alex Vittitow, Jenny Chen, Rita Obi, Daniel Schatz, Babak Tofighi, Ann Garment, Andrea Kermack, Keith Goldfeld, Heather Gold, Eugene Laska, John Rotrosen, Joshua Lee

Research output: Contribution to journalArticle

Abstract

Background: Extended-release naltrexone (XR-NTX, Vivitrol®)and daily oral naltrexone tablets (O-NTX)are FDA-approved mu opioid receptor antagonist medications for alcohol dependence treatment. Despite the efficacy of O-NTX, non-adherence and poor treatment retention have limited its adoption into primary care. XR-NTX is a once-a-month injectable formulation that offers a potentially more effective treatment option in reducing alcohol consumption and heavy drinking episodes among persons with alcohol use disorders. Methods: This pragmatic, open-label, randomized controlled trial examines the effectiveness of XR-NTX vs. O-NTX in producing a Good Clinical Outcome, defined as abstinence or moderate drinking (<2 drinks/day, men; <1 drink/day, women; and < 2 heavy drinking occasions/month)during the final 20 of 24 weeks of primary care-based Medical Management treatment for alcohol dependence. Secondary aims will estimate the cost effectiveness of XR-NTX vs. O-NTX, in conjunction with primary-care based Medical Management for both groups, and patient-level characteristics associated with effectiveness in both arms. Alcohol dependent persons are recruited from the community into treatment in a New York City public hospital primary care setting (Bellevue Hospital Center)for 24 weeks of either XR-NTX (n = 117)or O-NTX (n = 120). Results: We describe the rationale, specific aims, design, and recruitment results to date. Alternative design considerations and secondary aims and outcomes are reported. Conclusions: XR-NTX treatment in a primary care setting is potentially more efficacious, feasible, and cost-effective than oral naltrexone when treating community-dwelling persons with alcohol use disorders. This study will estimate XR-NTX's treatment and cost effectiveness relative to oral naltrexone.

Original languageEnglish (US)
Pages (from-to)102-109
Number of pages8
JournalContemporary Clinical Trials
Volume81
DOIs
StatePublished - Jun 1 2019

Fingerprint

Naltrexone
Alcoholism
Primary Health Care
Tablets
Drinking
Alcohols
Therapeutics
Cost-Benefit Analysis
Independent Living
Narcotic Antagonists
mu Opioid Receptor
Public Hospitals
Urban Hospitals
Alcohol Drinking
Health Care Costs
Randomized Controlled Trials
Costs and Cost Analysis
Injections

Keywords

  • Alcohol dependence
  • Alcohol use disorder
  • Extended-release naltrexone
  • Medical management
  • Naltrexone
  • Primary care treatment

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Malone, M., McDonald, R., Vittitow, A., Chen, J., Obi, R., Schatz, D., ... Lee, J. (2019). Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). Contemporary Clinical Trials, 81, 102-109. https://doi.org/10.1016/j.cct.2019.04.006

Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). / Malone, Mia; McDonald, Ryan; Vittitow, Alex; Chen, Jenny; Obi, Rita; Schatz, Daniel; Tofighi, Babak; Garment, Ann; Kermack, Andrea; Goldfeld, Keith; Gold, Heather; Laska, Eugene; Rotrosen, John; Lee, Joshua.

In: Contemporary Clinical Trials, Vol. 81, 01.06.2019, p. 102-109.

Research output: Contribution to journalArticle

Malone, M, McDonald, R, Vittitow, A, Chen, J, Obi, R, Schatz, D, Tofighi, B, Garment, A, Kermack, A, Goldfeld, K, Gold, H, Laska, E, Rotrosen, J & Lee, J 2019, 'Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON)', Contemporary Clinical Trials, vol. 81, pp. 102-109. https://doi.org/10.1016/j.cct.2019.04.006
Malone, Mia ; McDonald, Ryan ; Vittitow, Alex ; Chen, Jenny ; Obi, Rita ; Schatz, Daniel ; Tofighi, Babak ; Garment, Ann ; Kermack, Andrea ; Goldfeld, Keith ; Gold, Heather ; Laska, Eugene ; Rotrosen, John ; Lee, Joshua. / Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). In: Contemporary Clinical Trials. 2019 ; Vol. 81. pp. 102-109.
@article{eb18d282fbac4256b1e2fa6299a45a6a,
title = "Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON)",
abstract = "Background: Extended-release naltrexone (XR-NTX, Vivitrol{\circledR})and daily oral naltrexone tablets (O-NTX)are FDA-approved mu opioid receptor antagonist medications for alcohol dependence treatment. Despite the efficacy of O-NTX, non-adherence and poor treatment retention have limited its adoption into primary care. XR-NTX is a once-a-month injectable formulation that offers a potentially more effective treatment option in reducing alcohol consumption and heavy drinking episodes among persons with alcohol use disorders. Methods: This pragmatic, open-label, randomized controlled trial examines the effectiveness of XR-NTX vs. O-NTX in producing a Good Clinical Outcome, defined as abstinence or moderate drinking (<2 drinks/day, men; <1 drink/day, women; and < 2 heavy drinking occasions/month)during the final 20 of 24 weeks of primary care-based Medical Management treatment for alcohol dependence. Secondary aims will estimate the cost effectiveness of XR-NTX vs. O-NTX, in conjunction with primary-care based Medical Management for both groups, and patient-level characteristics associated with effectiveness in both arms. Alcohol dependent persons are recruited from the community into treatment in a New York City public hospital primary care setting (Bellevue Hospital Center)for 24 weeks of either XR-NTX (n = 117)or O-NTX (n = 120). Results: We describe the rationale, specific aims, design, and recruitment results to date. Alternative design considerations and secondary aims and outcomes are reported. Conclusions: XR-NTX treatment in a primary care setting is potentially more efficacious, feasible, and cost-effective than oral naltrexone when treating community-dwelling persons with alcohol use disorders. This study will estimate XR-NTX's treatment and cost effectiveness relative to oral naltrexone.",
keywords = "Alcohol dependence, Alcohol use disorder, Extended-release naltrexone, Medical management, Naltrexone, Primary care treatment",
author = "Mia Malone and Ryan McDonald and Alex Vittitow and Jenny Chen and Rita Obi and Daniel Schatz and Babak Tofighi and Ann Garment and Andrea Kermack and Keith Goldfeld and Heather Gold and Eugene Laska and John Rotrosen and Joshua Lee",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.cct.2019.04.006",
language = "English (US)",
volume = "81",
pages = "102--109",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON)

AU - Malone, Mia

AU - McDonald, Ryan

AU - Vittitow, Alex

AU - Chen, Jenny

AU - Obi, Rita

AU - Schatz, Daniel

AU - Tofighi, Babak

AU - Garment, Ann

AU - Kermack, Andrea

AU - Goldfeld, Keith

AU - Gold, Heather

AU - Laska, Eugene

AU - Rotrosen, John

AU - Lee, Joshua

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Background: Extended-release naltrexone (XR-NTX, Vivitrol®)and daily oral naltrexone tablets (O-NTX)are FDA-approved mu opioid receptor antagonist medications for alcohol dependence treatment. Despite the efficacy of O-NTX, non-adherence and poor treatment retention have limited its adoption into primary care. XR-NTX is a once-a-month injectable formulation that offers a potentially more effective treatment option in reducing alcohol consumption and heavy drinking episodes among persons with alcohol use disorders. Methods: This pragmatic, open-label, randomized controlled trial examines the effectiveness of XR-NTX vs. O-NTX in producing a Good Clinical Outcome, defined as abstinence or moderate drinking (<2 drinks/day, men; <1 drink/day, women; and < 2 heavy drinking occasions/month)during the final 20 of 24 weeks of primary care-based Medical Management treatment for alcohol dependence. Secondary aims will estimate the cost effectiveness of XR-NTX vs. O-NTX, in conjunction with primary-care based Medical Management for both groups, and patient-level characteristics associated with effectiveness in both arms. Alcohol dependent persons are recruited from the community into treatment in a New York City public hospital primary care setting (Bellevue Hospital Center)for 24 weeks of either XR-NTX (n = 117)or O-NTX (n = 120). Results: We describe the rationale, specific aims, design, and recruitment results to date. Alternative design considerations and secondary aims and outcomes are reported. Conclusions: XR-NTX treatment in a primary care setting is potentially more efficacious, feasible, and cost-effective than oral naltrexone when treating community-dwelling persons with alcohol use disorders. This study will estimate XR-NTX's treatment and cost effectiveness relative to oral naltrexone.

AB - Background: Extended-release naltrexone (XR-NTX, Vivitrol®)and daily oral naltrexone tablets (O-NTX)are FDA-approved mu opioid receptor antagonist medications for alcohol dependence treatment. Despite the efficacy of O-NTX, non-adherence and poor treatment retention have limited its adoption into primary care. XR-NTX is a once-a-month injectable formulation that offers a potentially more effective treatment option in reducing alcohol consumption and heavy drinking episodes among persons with alcohol use disorders. Methods: This pragmatic, open-label, randomized controlled trial examines the effectiveness of XR-NTX vs. O-NTX in producing a Good Clinical Outcome, defined as abstinence or moderate drinking (<2 drinks/day, men; <1 drink/day, women; and < 2 heavy drinking occasions/month)during the final 20 of 24 weeks of primary care-based Medical Management treatment for alcohol dependence. Secondary aims will estimate the cost effectiveness of XR-NTX vs. O-NTX, in conjunction with primary-care based Medical Management for both groups, and patient-level characteristics associated with effectiveness in both arms. Alcohol dependent persons are recruited from the community into treatment in a New York City public hospital primary care setting (Bellevue Hospital Center)for 24 weeks of either XR-NTX (n = 117)or O-NTX (n = 120). Results: We describe the rationale, specific aims, design, and recruitment results to date. Alternative design considerations and secondary aims and outcomes are reported. Conclusions: XR-NTX treatment in a primary care setting is potentially more efficacious, feasible, and cost-effective than oral naltrexone when treating community-dwelling persons with alcohol use disorders. This study will estimate XR-NTX's treatment and cost effectiveness relative to oral naltrexone.

KW - Alcohol dependence

KW - Alcohol use disorder

KW - Extended-release naltrexone

KW - Medical management

KW - Naltrexone

KW - Primary care treatment

UR - http://www.scopus.com/inward/record.url?scp=85065469005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065469005&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2019.04.006

DO - 10.1016/j.cct.2019.04.006

M3 - Article

VL - 81

SP - 102

EP - 109

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

ER -